Corporate presentation
Logotype for Cosciens Biopharma Inc

Cosciens Biopharma (CSCI) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Cosciens Biopharma Inc

Corporate presentation summary

13 Nov, 2026

Strategic transformation

  • Four directors appointed in May 2025; Ceapro and corporate cost reductions followed, alongside a strategic review focused on profitability and growth.

  • Ceased funding German subsidiaries in March 2026 and initiated insolvency proceedings; this eliminated ongoing operating-loss exposure and generated $10.9M of discontinued-operations income, with shareholders’ equity increasing 4X.

  • Shareholders approved a 1-for-150 consolidation followed by a 50-for-1 split; the share count fell by approximately two-thirds, and a July 2026 Form 15 filing was intended to save an estimated $1.9M in annual reporting costs.

  • Acquired Nualtis in September 2026 for $15M, with potential earn-outs of 10% of adjusted EBITDA for FY2027–FY2030; Nualtis adds oral-film technology and pharmaceutical development and manufacturing capabilities.

Operating platforms

  • Ceapro develops and manufactures oat- and plant-derived actives for personal care, cosmetics, human health, and animal health; its Edmonton GMP facility supports R&D, pilot, and commercial production.

  • Ceapro’s portfolio includes oat beta glucan, avenanthramides, superfine oat flour, oat oil, and oat peptides; products serve skin care, hair care, sensitive skin, and animal and pet markets.

  • Ceapro’s proprietary extraction, chromatography purification, and PGX processing complement non-GMO oat inputs, quality documentation, and distribution partners across multiple markets.

  • Ceapro generates approximately $9M in revenue, growing at circa 5% annually, with an approximately $2M annualized EBITDA run rate; core assets include a 30,000 sq. ft. Edmonton GMP plant.

  • Nualtis operates a Montreal GMP facility and develops human and veterinary oral thin films through VersaFilm and VetaFilm; its platform is supported by 30+ U.S. patents and patent applications.

Nualtis market and pipeline

  • Oral thin films are cited as a $3.8B global market in 2024, projected to reach $8.4B by 2033 at a 9.3% CAGR; sublingual films represented 63% of the 2024 market.

  • Nualtis has 20+ years of R&D experience and a diversified human- and animal-health pipeline, with multiple assets in approval stages and revenue potential from services, manufacturing, milestones, and royalties.

  • Pipeline molecules include rizatriptan, buprenorphine, buprenorphine/naloxone, tadalafil, montelukast, and undisclosed candidates across indications including migraine, pain, opioid use disorder, and animal health.

  • A buprenorphine product is subject to ongoing patent litigation; an adverse outcome could materially delay its commercial launch.

  • Nualtis is expected to generate approximately $6M in 2026 revenue and be small EBITDA positive; successful pipeline commercialization could produce tens of millions of dollars in annual revenue within five years, with an approximately 40% EBITDA margin at that revenue level.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cosciens Biopharma